Miopatías inflamatorias con evolución recidivante / Relapses in inflammatory myopathies

La mayoría de los estudios de tratamiento de las miopatías inflamatorias son de corte y no permiten establecer su eficacia en largo plazo. En este trabajo, describimos el seguimiento de siete pacientes con miopatías inflamatorias, 5 polimiositis y 2 dermatomiositis. Determinamos su presentación, su seguimiento clínico mediante el examen físico, las enzimas musculares y la respuesta al tratamiento. Esta última la definimos como cursos de tratamiento, donde cada curso termina al aumentar los corticoides o al colocar una nueva medicación inmunosupresora debido al empeoramiento clínico o aumento sostenido de las enzimas musculares. El tratamiento instaurado puede remitir, controlar parcialmente, o fracasar en controlar la enfermedad en cuanto se normalicen, estabilicen, o no modifiquen respectivamente tanto la clínica como las enzimas musculares. Se analizaron 20 ciclos, en 14 se logró la remisión, en cinco se controló parcialmente y en uno fracasó el tratamiento. La remisión se logró en un tiempo promedio de 139 ± 98 días y el control en un promedio de 160 ± 100 días. Excepto en una ocasión, todos los ciclos de tratamiento, independientemente del que fuera, remitieron o controlaron los síntomas, pero en el tiempo todos los pacientes recidivaron en su enfermedad.

Most studies about treatment of inflammatory myopathies consist of cross-sectional analyses that do not assess long-term efficacy. In the present study we describe the follow-up of seven patients with inflammatory myopathies, 5 polymyositis and 2 dermatomyositis. We describe their clinical features, follow-up, muscle enzyme levels, and treatment responses. We define the latter as treatment cycles, every one of which end when steroid doses need to be increased or a new immunosuppressive drug has to be added because of clinical worsening or sustained increases in muscle enzyme levels. Treatment can cause remission, partially control, or fail in achieving myositis improvement when it normalizes, stabilizes, or does not affect muscle enzymes or clinical features, respectively. We analyzed 20 cycles, in which remission was achieved in 14 cases, partial control in 5 instances, and treatment failure in one case. Remission occurred after an average of 139 ± 98 days, whereas partial control took place in 160 ± 100 days. Except in one case, all treatment cycles controlled or remitted the symptoms. However, in all patients the illness recurred with time.

Polymyositis presenting with respiratory failure.

Polymyositis is a systemic autoimmune disorder characterised by inflammatory myopathy of the skeletal muscles predominantly affecting the proximal muscles and associated with extra-muscular manifestations like dysphagia and skin involvement. In this case report, we describe the occurrence of diaphragmatic weakness and respiratory failure due to polymyositis with relatively well preserved power in limb muscles.

Hiponatremia y terapia con inmunoglobulina endovenosa: a propósito de un paciente consíndrome de sobreposición / Hyponatremia and therapy with intravenous immunoglobulin: about a patient with overlap syndrome

El uso de inmunoglobulina endovenosa está cada vez más difundido, tanto para inmunodeficiencias como para enfermedades de orden autoinmune, infecciosas, así como de tipo neurológico. Si bien la infusión de ésta se asocia con algunos efectos adversos sintomáticos, también es cierto que varios pasan desapercibidos. Se presenta el caso de una paciente con síndrome de sobreposición (polimiositis y esclerodermia), la que durante el procedimiento presenta una pseudohiponatremia asociada a una excelente respuesta clínica a este fármaco. Es importante recalcar que esta complicación sólo corresponde a un hallazgo y no tiene indicación de suspender la terapia.

The use of intravenous immunoglobulin is becoming increasingly widespread, for immunodeficiencies, autoimmune, infectious and neurological diseases. Although this infusion is associated with some symptomatic adverse effects, it is also true that many go unnoticed. A case of a patient with overlap syndrome (polymyositis and scleroderma) is reported, who presented with a pseudohiponatremia associated with excellent clinical response to this. It is important to emphasize that this complication only corresponds to a finding and it is not an indication to discontinue the therapy.

Miopatias inflamatórias idiopáticas: relato de caso / The idiopathic inflammatory myopathies: case report

JUSTIFICATIVA E OBJETIVOS: As miopatias inflamatórias idiopáticas, também conhecidas como síndrome de miosite, são da família de doenças sistêmicas adquiridas do tecido conjuntivo, caracterizadas por efeitos clínicos e patológicos de inflamação muscular crônica de causa desconhecida. As formas mais comuns são a polimiosite e a dermatomiosite, que tem seu diagnóstico com base em uma combinação de achados clínicos, laboratoriais e histopatológicos. O objetivo deste estudo foi abordar a característica clínica da dermatopolimiosite e demonstrar a evolução e o tratamento da doença. RELATO DO CASO: Paciente do sexo feminino, 66 anos, apresentando quadro de dor no abdômen e nos membros superiores e inferiores, associada com diminuição da força muscular. Presença de dispnéia acompanhada de tosse produtiva. Foi submetida à avaliação reumatológica, levantando-se a hipótese de dermatopolimiosite, concluindo-se o diagnóstico após avaliação clinica e laboratorial. CONCLUSÃO: O tratamento da doença ocorreu de acordo com o padrão evolutivo que a paciente se encontrava.

BACKGROUND AND OBJECTIVES: The idiophatic inflammatory myopathies - or syndrome myositis - are a group of acquired systemic diseases of connective tissue with characteristic of clinical and pathological effect of chronic inflammatory of muscle whose your pathogenesis is strange. The types habitual are the polymyositis and the dermatomyositis. For diagnosis is necessary a arrangement of clinical, laboratory and histopathologic founds. In this article we approach the characteristics of idiopathic inflammatory myopathies, aiming to demonstrate the evolution and treatment of disease. CASE REPORT: Female patient, 66 years, presenting chart of pain in abdomen and lower and upper members, associated with diminution of the muscular force. Presence of dyspnea accompanied of productive cough. It was submitted to Rheumatologic clinical evaluation being raised the hypothesis of dermatopolymyositis, concluding the diagnosis after evaluation is in clinical practice and laboratory. CONCLUSION: The handling of the illness occurs according to the developing standard that the patient is found.

Polymyositis: rare complication of hepatitis B vaccination. An unusual cause of toxic shock syndrome

Transient weakness of the legs developed in a 17 year-old male high school student three weeks after the initial injection of a hepatitis B vaccine. Seventeen days after the second injection of the vaccine, low-grade fever, a pruritic maculopapular rash appeared and weakness of the legs recurred. This was associated with elevation of the creatinine kinase to 2,406 U/L. The day after admission he became afebrile and in the subsequent four days the rash improved but leg weakness persisted. One-month later, muscle strength had returned; and the creatinine kinase had returned to normal levels. The only case of dermatomyositis associated with hepatitis B vaccination and the findings in the six reported cases of surface antigen-positive hepatitis associated with polyomyositis or dermatomyositis are briefly reviewed. Hepatitis B vaccination should be encouraged, but it is important to be aware that, rarely, dermatomyositis, polymyositis or neurovascular complications may occur. Polymyositis associated with the administration of the hepatitis B vaccine or with hepatitis B virus infection is a rare occurrence. A Medline Search performed from 1960 to January 2002 associating hepatitis B vaccine or hepatitis B virus with myopathy, myositis, polymyositis and dermatomyositis, showed only one case of dermatomyositis related to the hepatitis B vaccine, and six case reports relating polymyositis to hepatitis B virus infection. We present a case where a causal relationship between polymyositis and hepatitis B vaccination appears quite likely

Successful Combination Therapy of Cyclosporine and Methotrexate for Refractory Polymyositis with Anti-Jo-1 Antibody: A Case Report

Although corticosteroids have been the initial agent for the treatment of inflammatory myopathies (IM), immunosuppressive agents such as azathioprine, methotrexate, cyclophosphamide, or cyclosporine are commonly required to control the disease except mild cases. On the other hand, the efficacy of combination therapy of cyclosporine and methotrexate in severe rheumatoid arthritis has been proven without serious side effects. However, in treatment-resistant myositis, the experience of such a therapy is very limited, and has not been described in refractory polymyositis with anti-Jo-1 antibody. Here, we report a young female patient with recalcitrant polymyositis and anti-Jo-1 antibody who was successfully treated with the combination therapy of cyclosporine and methotrexate. At first, the myositis did not respond to several agents, such as corticosteroid, monthly pulse cyclophosphamide, azathioprine, or cyclosporine. Methotrexate was initially avoided as treatment regimen because of its potential pulmonary toxicity in the case with preexisting lung disease.

Polidermatomiositis y embarazo / Polidermatomyositis and pregnancy

Presentamos dos casos de esta rara miopatía durante el embarazo, enfatizando su condición de alto riesgo obstétrico perinatal, resaltamos el muy mal pronóstico gestacional dejadas evolucionar espontaneamente y la probable relación de este mal pronóstico con la concomitancia de anticuerpos anticardiolipinas

Corticotherapie et maladies systemiques

Corticosteroid are an essential mean to overcome systemic disorders. Thirty years ago they changed the prognosis of most of these diseases. Adverse effects are numerous and dangerous, especially infectious diseases and bone disorders. Prednisone is the most used drug. The pulse of methyprednisone is less used. In this study, we discuss some principles of the use of corticosteroid and the problems encountered using corticotherapy in systemic disorders